Ibandronic Acid Sandoz (ibandronic acid)
Generic
- Region
- 🇪🇺 EU
- Active substance
- ibandronic acid
- Company
- Sandoz GmbH
- Status
- Lapsed
- Therapeutic area
- Breast Neoplasms; Neoplasm Metastasis; Fractures, Bone
- CHMP opinion
- Thu 17 Feb 2011
- EU approval
- Tue 26 Jul 2011
- Designations
- Generic
- Application
- EMEA/H/C/002367
- ATC
- M05BA06
- Official record
- www.ema.europa.eu
Indication
Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Iasibon Authorised · Pharmathen S.A.
- 🇪🇺 Ibandronic acid Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Bonviva Authorised · Atnahs Pharma Netherlands B.V.
- 🇪🇺 Bondronat Authorised · Atnahs Pharma Netherlands B.V.
- 🇪🇺 Ibandronic Acid Teva Authorised · Teva Pharma B.V.
- 🇪🇺 Bondenza (previously Ibandronic Acid Roche) Withdrawn · Roche Registration Ltd.
- 🇪🇺 Ibandronic Acid Hexal Application withdrawn · Hexal AG
- 🇪🇺 Destara Withdrawn · Roche Registration Ltd.
Follow Ibandronic Acid Sandoz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.